Literature DB >> 8915232

Etiology and prognostic significance of eosinophilic pleural effusions. A prospective study.

J B Rubins1, H B Rubins.   

Abstract

STUDY
OBJECTIVE: To determine the diagnostic and prognostic significance of eosinophilic pleural effusions.
DESIGN: A prospective cohort study of patients undergoing thoracentesis between September 1990 and September 1995.
SETTING: A university-affiliated VA Medical Center. PATIENTS: Four hundred seventy-six consecutive patients. MEASUREMENTS AND
RESULTS: Eosinophilic pleural effusions were identified in 44 of the 476 patients (9.2%). Malignancy was diagnosed as frequently in eosinophilic as in noneosinophilic effusions (20.5% vs 20.1%). The only diagnoses that were significantly associated with eosinophilic effusions were idiopathic (25% vs 8%; p = 0.001) and postthoracic surgery (11% vs 3%; p = 0.023). Median survival was 7.7 months for those with a noneosinophilic effusion compared to 16.8 months for those with eosinophilia (p = 0.017). This difference in survival persisted after adjustment for age and diagnosis.
CONCLUSIONS: We conclude that malignancy is as prevalent among eosinophilic as noneosinophilic pleural effusions. However, the survival of patients with pleural fluid eosinophilia may be better than that of patients with noneosinophilic effusions.

Entities:  

Mesh:

Year:  1996        PMID: 8915232     DOI: 10.1378/chest.110.5.1271

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate?

Authors:  L Sølling Avnon; M Abu-Shakra; D Flusser; D Heimer; N Sion-Vardy
Journal:  Rheumatol Int       Date:  2007-02-09       Impact factor: 3.580

2.  Pirfenidone-induced Eosinophilic Pleurisy.

Authors:  Isano Hase; Bunpei Yamaguchi; Hidenori Takizawa; Hiroaki Arakawa; Hideo Sakuma; Koichi Fujiu; Hideaki Miyamoto; Yoshiki Ishii
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

3.  Eosinophilic pleural effusion as a manifestation of taeniasis.

Authors:  Synrang Batngen Warjri; Tony Ete; Habung Mobing; Narang Naku; Vanlalmawsawmdawngliana Fanai; Shakeel Ahamad Khan; Arun Kumar; Animesh Mishra
Journal:  Autops Case Rep       Date:  2020-11-20

Review 4.  Serous fluids and hematolymphoid disorders.

Authors:  Ali Gabali
Journal:  Cytojournal       Date:  2022-03-19       Impact factor: 2.345

5.  Eosinophilic pleural effusion and giardiasis: A causal or a casual relationship?

Authors:  Urvinderpal Singh; Nishi Garg; Vishal Chopra
Journal:  Lung India       Date:  2013-01

6.  Recurrent post-traumatic non-eosinophilic pleural effusion: report of three cases.

Authors:  Artur Eugênio de Azevedo Pereira; Ricardo Mingarini Terra; Lisete Ribeiro Teixeira; Paulo Manuel Pêgo-Fernandes; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

7.  Intrapleural corticosteroid injection in eosinophilic pleural effusion associated with undifferentiated connective tissue disease.

Authors:  Eunjung Kim; Changhwan Kim; Bokyung Yang; Mihee Kim; Jingu Kang; Jiun Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-10-29

8.  Diagnostic procedure for idiopathic eosinophilic pleural effusion: a single-center experience.

Authors:  Weizhan Luo; Yunxiang Zeng; Panxiao Shen; Jianxing He; Jinlin Wang
Journal:  BMC Pulm Med       Date:  2020-04-03       Impact factor: 3.317

9.  Incidence, aetiology and clinical features of eosinophilic pleural effusion: a retrospective study.

Authors:  Minfang Li; Yunxiang Zeng; Sheng Chen; Jinlin Wang; Yaqing Li; Dan Jia
Journal:  BMC Pulm Med       Date:  2021-12-06       Impact factor: 3.317

10.  Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion.

Authors:  Eiji Takeuchi; Yoshio Okano; Hisanori Machida; Katsuhiro Atagi; Yoshihiro Kondou; Naoki Kadota; Nobuo Hatakeyama; Keishi Naruse; Tsutomu Shinohara
Journal:  Cancer Immunol Immunother       Date:  2021-06-25       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.